$DGX

Quest Diagnostics Q3 2026 slides: 10% revenue growth, raised outlook

Quest Diagnostics (NYSE:DGX) reported Q3 2026 revenue of $3.10B, up 10% YoY, and raised full-year guidance. Adjusted EPS grew 15.4% to $3.00. The company cited strong volume growth and strategic initiatives in Alzheimer's diagnostics and consumer health. Shares rose 0.84% to $240.93, near a 52-week high. Challenges include PAMA reimbursement cuts and Project Nova costs.

Original reporting
Published Oct 22, 2026, 1:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 2:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DGX
Bullish
high confidence
Mentioned
$DGX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DGXBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to boost the stock in the short term.

02

Market read

First report of earnings and guidance raise for a large-cap healthcare company.

03

What to watch

Potential PAMA reimbursement cuts in 2027 and Project Nova costs could pressure margins.

Relevance 8/10Novelty 9/10Timing: today

Background

Quest Diagnostics (DGX) released its Q3 2026 earnings, showing organic growth and raised guidance.

Company-level read

Ticker impact

$DGXBullishHigh confidence
Context

Quest Diagnostics reported Q3 2026 results with 10% revenue growth and raised full-year guidance.

Expected impact

upside pressure as investors price in higher revenue and EPS outlook

Evidence & confidence

Revenue up 10% YoY and EPS guidance increased to $11.25-$11.35, indicating stronger profitability.

Market effects

Strengthens outlook for the diagnostic services sector, may lift peers.

Positive for US healthcare stocks.

Limited to healthcare investors, no broad macro effect.

Counterpoint

If guidance is overly optimistic, a miss on future quarters could trigger a pullback.

Key entities

  • Quest Diagnostics

    Diagnostic testing leader reporting Q3 results.

Related articles

$DGXLow

Quest Diagnostics Reports Hack on IT System Used by Clients

Quest Diagnostics reported a cyber incident involving its Quanum Lab Services Manager system, potentially compromising certain patient records. The company paused access to the system while investigating but stated it has not materially disrupted operations. Quest notified U.S. law enforcement and is taking remedial measures. The company reported $11.04 billion in revenue for 2025. This follows recent cyber incidents at Abbott Labs, which is facing lawsuits.

$DGXMed

Quest Diagnostics Inc (DGX) (Q3 2026) Earnings Call Highlights: Double-Digit Revenue

Quest Diagnostics (DGX) reported Q3 2026 earnings with double-digit revenue growth, but faces challenges. PAMA reimbursement cuts may impact 2027 revenues by 1%. Total revenue per requisition declined 4.2% due to business mix, though it rose 1.7% excluding certain relationships. The company also reported a cybersecurity incident and higher fuel costs. CEO Jim Davis and CFO Sam Samad discussed growth strategies, partnerships, and margin improvements.

$DGXMed

Northern Light Health lab manager suffers data breach

Quest Diagnostics reported a cyber breach in its Quanum Lab Services Manager, potentially compromising patient records. The breach, discovered Wednesday, is under investigation. Quest manages labs for Northern Light Health, which stated no indication of its patients being impacted. Quest has notified law enforcement and is working with cybersecurity experts. The company has experienced similar breaches in 2016 and 2019.

$DGXHighAI 8/10

What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call

Quest Diagnostics (DGX) reported Q3 operating income of $479M, up from $386M YoY. Adjusted EPS rose 15.4% to $3.00. The company expects full-year 2026 revenue of $12.065B-$12.105B. Quest plans to acquire select assets from a health system in the Northeastern U.S. and launched consumer health services via Apple Health app. Management addressed PAMA concerns, estimating a 1% revenue impact in 2027.

$DGXHighAI 8/10

Quest Diagnostics (DGX) Q3 2026 Earnings Call Transcript

Quest Diagnostics (DGX) raised its full-year revenue and earnings guidance after Q3 2026, citing strong performance across physician, hospital, and consumer health channels. Key growth drivers include collaborations, acquisitions, and innovative solutions like Apple Health app integration. The company also announced plans to expand its Alzheimer's disease testing portfolio and improve operational efficiency through automation and AI.